Brought to you by 
Sanofi outbids Novo with €45 per share offer for Ablynx, total of €3.8bn
30 Aug 2021
Executive Summary
Public Belgian biotech Ablynx NV agreed to be acquired by Sanofi, which offered €45 per share ($59.92; a 37% premium) for a fully diluted equity value of €3.8bn ($5.1bn). The deal trumps an offer made earlier this month by Novo, which bid €28 per share plus CVRs for a total value of €2.3bn. Ablynx shareholders repeatedly rejected Novo’s advances, and Novo has stated that it will not make a revised offer.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Earnout
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sanofi outbids Novo with €45 per share offer for Ablynx, total of €3.8bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice